The Fermiscan Test is a safe, non-invasive technology that utilises X-ray diffraction of hair fibres to screen and monitor women of all ages for breast cancer. The Fermiscan Test will be available for women in Australia in 2008 and Fermiscan is also commencing further clinical trials and regulatory approval processes in the US.
The Fermiscan Test requires individuals to supply 20 strands of untreated scalp hair with a minimum length of 30 mm. The hairs are then exposed to a finely focused X-ray beam for up to 30 s. The diffracted X-rays are collected as an image which is then analysed to determine if subtle changes are present in the image that are indicative of the presence of breast cancer.
Phone: 02 9245 4460
Lumiprobe SynaptoProbe Red dye for visualising synaptic vesicles in living neurons
Lumiprobe's SynaptoProbe Red is an analogue of FM 4-64, a widely used red fluorescent dye for...
Parse Biosciences Evercode Low Input Fixation kits for cells and nuclei
The kits empower researchers who have a small number of starting cells or nuclei who ordinarily...
EpigenTek MethylFlash Hydroxymethylated DNA Quantification Kit (Fluorometric)
The kit is a complete set of optimised buffers and reagents to fluorometrically quantify global...
